Speaker Profile
Biography
Mark McCarthy is Executive Director of Human Genetics at Genentech, where he leads efforts within the company to use human genetics to advance the understanding of disease and further the development of novel therapeutic and preventative approaches. Prior to his move to the Bay Area in 2019, Mark was Robert Turner Professor of Diabetes Medicine at the University of Oxford. There, his research focused on genetic discovery in type 2 diabetes and related traits, and on using the causal insights derived from those analyses to drive biological inference and translational opportunities.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: TBA
PMWC Award Ceremony Honorees
• Mark Daly, Broad Institute
• Daniel MacArthur, CPG/Genomes/gnomAD
• Gordon Sanghera, Oxford Nanopore
• Howard J. Jacob, Abbvie
The Data Factory: Building Systems to Integrate Millions of Genomes for Variant Interpretation
• Chair: Stephen B. Montgomery, Stanford
• Carlos D. Bustamante, University of Oklahoma
• Mark Daly, Broad Institute/FinnGen
• Manuel Rivas, Stanford
• Mark McCarthy, Genentech
• Nilah Ioannidis, UC Berkeley
Biobanks to Bedside: Cutting VUS in Cancer, Cardio & Rare—What’s Working Now
• Chair: Ben Neale, Broad Institute
• Daniel MacArthur, CPG/Genomes/gnomAD
Beyond the Read: Integrating Long-Read Data into the Clinical Variant Pipeline
• Chair: Gordon Sanghera, Oxford Nanopore Technologies
• Hanlee P. Ji, Stanford
DNA to FDA: How Genetic Targets Win Labels & Coverage
• Russ B. Altman, Stanford
Common Diseases in Clinical Cohorts – Not Always What They Seem
• Howard J. Jacob, Abbvie
DNA to FDA: How Genetic Targets Win Labels & Coverage
• Chair: Razelle Kurzrock, Medical College of Wisconsin
• Russ B. Altman, Stanford
25+ Years of the Human Genome — What Made It to the Bedside
• Chair: Ralph Snyderman, Duke
• J. Craig Venter, Craig Venter Institute (JCVI)
• Brook Byers, KPCB
• Lee Hood, Phenome Health




